Last reviewed 2026-05-25 · How we verify

Barbexaclon (BARBEXACLONE)

Phase 2 active Small molecule ✓ Verified May 2026

Barbexaclon (generic name: BARBEXACLONE) is a barbexaclone drug. It is currently in Phase 2 development.

Barbexaclon is thought to work by modulating ion channels in the brain, although the exact details of its mechanism are unclear.

Barbexaclon is a small molecule with an unknown mechanism of action. It is also known by other names, including Barbexaclona, Barbexaclone, Maliasin, and Propylhexedrine L-form Ethylphenylbarbiturate.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	BARBEXACLONE
Drug class	barbexaclone
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your brain cells are like doors that open and close to let certain messages in or out. Barbexaclon is believed to affect these doors, helping to regulate the flow of information between brain cells. This can potentially help with various conditions, but more research is needed to understand how it works and what benefits it might provide.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Barbexaclon CI brief — competitive landscape report
Barbexaclon updates RSS · CI watch RSS

Frequently asked questions about Barbexaclon

What is Barbexaclon?

Barbexaclon (BARBEXACLONE) is a barbexaclone drug.

How does Barbexaclon work?

Barbexaclon is thought to work by modulating ion channels in the brain, although the exact details of its mechanism are unclear.

What is the generic name of Barbexaclon?

BARBEXACLONE is the generic (nonproprietary) name of Barbexaclon.

What drug class is Barbexaclon in?

Barbexaclon belongs to the barbexaclone class. See all barbexaclone drugs at /class/barbexaclone.

What development phase is Barbexaclon in?

Barbexaclon is in Phase 2.

Drug class: All barbexaclone drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing